Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data show survival benefit of Arimidex over tamoxifin in early breast cancer
January 12th, 2006
New data presented show breast cancer treatment Arimidex (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in the treatment of hormone-sensitive early breast cancer and can significantly reduce recurrence, prevent metastatic spread and ultimately save lives. According to a new analysis of data presented at a leading breast cancer symposium in San Antonio, Texas (SABCS), by replacing tamoxifen with anastrozole, postmenopausal women being treated for early breast cancer are not only able to almost halve the likelihood of their disease returning, but more importantly, reduce their risk of dying by nearly a...
Source: Women's Health Weekly (2006-01-12)
|
